Breaking News
Get 40% Off 0
Is NVDA a 🟢 buy or 🔴 sell? Unlock Now

Pfizer's COVID outlook cuts hit other vaccine maker shares

Published Oct 16, 2023 03:59AM ET Updated Oct 16, 2023 01:11PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: A vial of Biontech-Pfizer's Comirnaty vaccine against COVID-19 and syringes are seen during vaccination at the Institute for Health and Food Safety of Zenica, Bosnia and Herzegovina, December 16, 2021. REUTERS/Dado Ruvic/File photo
 
PFE
-0.64%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
BNTX
-0.43%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Michael Erman, Ludwig Burger and Manas Mishra

(Reuters) -Pfizer set off a fresh round of concern about the size of the U.S. COVID-19 vaccine and treatment market in the long term, driving down shares on Monday of its German partner BioNTech (NASDAQ:BNTX) and smaller rival Moderna (NASDAQ:MRNA).

Vaccine makers are depending on the U.S. market as many countries have more limited yearly campaigns for giving updated shots. For BioNTech, Moderna, and Novavax (NASDAQ:NVAX), COVID vaccines remain their only approved products.

BioNTech shares dropped 7.2% in Frankfurt trading while Moderna was down 5% and shares of Novavax, whose new shot is only approved in the U.S., were off 7% in New York.

Shares of Pfizer (NYSE:PFE) were up nearly 5%, however, buoyed by a $3.5 billion cost-cutting plan the drugmaker announced late on Friday alongside its new COVID sales outlook.

Pfizer reduced its full-year forecast for sales of its antiviral COVID treatment Paxlovid by about $7 billion, and for the vaccine it developed with BioNTech by about $2 billion due to a plunge in use of pandemic-related products. It said it would make cuts this year and next and take a write-down.

On an early Monday call with analysts, Pfizer CEO Albert Bourla said he expects around 17% of the U.S. population will get updated COVID shots during the current vaccination campaign, in line with last year, but far below rates seen when vaccines first emerged in the spring of 2021.

Going forward, Bourla said the company expects this year's demand to be the base rate but it was still watching the current campaign to be sure.

The U.S. is "in the middle of COVID fatigue, where everyone wants to forget about the disease," he said.

Moderna, in a statement on Monday, maintained its current revenue forecast of $6 billion to $8 billion for its COVID vaccine for 2023.

Leerink analyst Mani Foroohar, who has an "underperform" rating on Moderna, said it is difficult to have confidence in the company's market forecast given the pace of vaccinations. So far this fall, about 7 million of the updated COVID shots have been given in the U.S.

Foroohar said he is concerned with Moderna's rate of spending and that the drugmaker is at risk of ending this year with less than $10 billion of cash on its balance sheet, adding that it may need to increase cost cutting.

Jefferies analyst Michael Yee said Pfizer's new COVID outlook implies lower vaccine sales for Moderna than it had forecast.

Moderna was not immediately available for comment.

BioNTech, which relies on vaccine-related profit-sharing payments from Pfizer for much of its revenue, said it would take a write-down of up to 900 million euros ($947 million), the same size charge Pfizer announced for it on Friday.

BioNTech added that it had been told by Pfizer that most of the write-offs relate to raw materials, as well as to inventories of vaccine versions that are older or different from the updated one currently in use.

Pfizer's total non-cash charge of $5.5 billion in the third quarter also includes $4.6 billion in inventory write-offs for its antiviral Paxlovid.

A BioNTech spokesperson on Monday declined to comment on the company's current 2023 outlook. It reports earning on Nov. 6.

Pfizer's shares, which are down about 37% this year, trade at 9.8 times their 12-month forward earnings estimate, while BioNTech trades at 26.7, according to LSEG data.

($1 = 0.9498 euro)

Pfizer's COVID outlook cuts hit other vaccine maker shares
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (3)
Joseph Lee
Joseph Lee Oct 16, 2023 10:37AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
A company of and for criminals.
John Weed
John Weed Oct 16, 2023 9:59AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Kelce isn’t boosting (ha ha) sales, Swift should give it a try
Conrad Conrad
Conrad Conrad Oct 16, 2023 6:45AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Big Pharma equals organized crime. Bourla received $9.8MM in compensation for 2018, 2022, $30.5MM! Thank god for Covid. Now, all that free Tax Payer money that flooded into the coffers of Pfizer and handed out all around to exec's has evaporated; more intelligent populous? I doubt it. Now Pfizer is going to take a non-cash charge against free money given to them from the Tax Payers! So they get free money, and pay no taxes. But you are going to have 70,000 IRS agents beating down the doors of Ebay sellers who didn't report $600+ in sales.
Brad Albright
Brad Albright Oct 16, 2023 6:45AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Yeah! All this IRS agents beating down doors and answering phones so that people can finally get a question answered. IT'S CRIMINAL!
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email